Processa Pharmaceuticals, Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Stockholders??? Equity (Details Narrative)

Stockholders’ Equity (Details Narrative)											1 Months Ended	12 Months Ended
Stockholders’ Equity (Details Narrative)	Nov. 01, 2021 shares	Oct. 06, 2021 USD ($) shares	Aug. 20, 2021 USD ($)	Aug. 05, 2021 shares	Jul. 01, 2021 shares	Jun. 16, 2021 shares	Jun. 08, 2021 shares	Feb. 24, 2021 USD ($) shares	Dec. 15, 2020 $ / shares shares	Oct. 06, 2020 USD ($) $ / shares shares	Aug. 31, 2020 shares	Dec. 31, 2021 USD ($) $ / shares shares	Dec. 31, 2020 USD ($) shares	Jan. 01, 2022 shares	Feb. 16, 2021 $ / shares shares
Class of Stock [Line Items]
Common stock, shares authorized												30,000,000	30,000,000
Preferred stock, shares issued												0	0
Preferred stock, shares outstanding												0	0
Net proceeds from public offering \| $								$ 9,900,000		$ 17,100,000
Number of shares, granted												17,800
Shares issued, price per share \| $ / shares										$ 4.00
Shares issued due to full-ratchet anti-dilution adjustment, shares													1,156,487
Fair value of warrants \| $												$ 391,108
Common Stock [Member]
Class of Stock [Line Items]
Shares issued during period, shares												100,000	28,971
Shares issued due to full-ratchet anti-dilution adjustment, shares													1,156,487
2019 Senior Notes [Member]
Class of Stock [Line Items]
Shares issued, price per share \| $ / shares										4.00
Number of common stock converted									247,088
Debt Instrument, Convertible, Conversion Price \| $ / shares									$ 3.60
Debt Instrument, Convertible, Conversion Ratio									0.10
Fair value of warrants \| $													$ 197,403
Common Stock [Member]
Class of Stock [Line Items]
Shares issued during period, shares												1,321,132
Number of shares, granted		17,800
Shares issued, price per share \| $ / shares										$ 4.00
Shares issued due to full-ratchet anti-dilution adjustment, shares													1,156,487
Common Stock [Member] \| Line of Credit [Member]
Class of Stock [Line Items]
Debt conversion converted, amount \| $										$ 700,000
Debt conversion converted, shares										199,537
Common Stock [Member] \| Underwritten Public Offering [Member]
Class of Stock [Line Items]
Shares issued during period, shares										4,800,000
Restricted Stock [Member]
Class of Stock [Line Items]
Number of shares, granted												37,500	336,860
Number of shares, forfeited												10,706	23,804
Number of shares, vested		12,500		55,143								281,721
Restricted Stock [Member] \| Underwritten Public Offering [Member]
Class of Stock [Line Items]
Number of shares, vested										214,078
Restricted Stock [Member] \| Employment Termination [Member]
Class of Stock [Line Items]
Number of shares, forfeited												1,530
Restricted Stock [Member] \| Federal, State and Local [Member]
Class of Stock [Line Items]
Number of shares, forfeited												9,176	23,804
Restricted Stock Units (RSUs) [Member]
Class of Stock [Line Items]
Number of shares, granted												457,593
Number of shares, forfeited												4,000
Number of shares, vested												14,000
Restricted Stock Units (RSUs) [Member] \| 2019 Omnibus Incentive Plan [Member]
Class of Stock [Line Items]
Shares issued during period, shares												14,300
Employees [Member] \| Restricted Stock [Member]
Class of Stock [Line Items]
Number of shares, granted							37,500
Employees [Member] \| Restricted Stock Units (RSUs) [Member]
Class of Stock [Line Items]
Number of shares, granted					202,930							144,457
Number of shares, forfeited					4,000
Number of shares, vested	39,786
Consultants [Member]
Class of Stock [Line Items]
Options and warrants granted												180,000
Private Placement [Member]
Class of Stock [Line Items]
Shares issued during period, shares								1,321,132
Gross proceeds from issuance of common stock \| $								$ 10,200,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights															79,268
Private Placement [Member] \| Placement Agent [Member]
Class of Stock [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights															79,268
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares															$ 9.30
Warrants and Rights Outstanding, Maturity Date															Feb. 16, 2023
License Agreement [Member] \| Ocuphire Pharma Inc [Member]
Class of Stock [Line Items]
Shares issued during period, shares						44,689
License Agreement [Member] \| Elion [Member]
Class of Stock [Line Items]
Shares issued during period, shares		100,000											825,000
Payment for license grant \| $													$ 100,000
License Agreement [Member] \| Aposense [Member]
Class of Stock [Line Items]
Shares issued during period, shares													625,000
License Agreement [Member] \| Yuhan [Member]
Class of Stock [Line Items]
Shares issued during period, shares											250,000		250,000
Sales Agreement [Member]
Class of Stock [Line Items]
Shares issued during period, shares												21,597
Gross proceeds from issuance of common stock \| $												$ 179,831
Fair value of maximum offering shares \| $			$ 30,000,000.0
Transaction costs, percentage			3.00%
Shares issued, price per share \| $ / shares												$ 8.33
Service Vesting [Member] \| Consultant [Member]
Class of Stock [Line Items]
Fair value of equity granted \| $		$ 743,378
Subsequent Event [Member]
Class of Stock [Line Items]
Common stock, shares authorized														50,000,000